Illinois Removes Testosterone from State Monitoring Program, Expands Trans Health Protections
Illinois is building legal barriers against medical surveillance, treatment disruption, and the administrative reversal of protections for trans people.
Illinois has removed testosterone from its Prescription Monitoring Program and enacted two additional laws strengthening access to hormone therapy and gender-marker protections for trans people.
Gov. JB Pritzker signed HB 4834, HB 5095, and HB 5492 on June 28. Together, the measures confront three systems that can be used to expose, obstruct, or control trans people: a government database containing sensitive prescription information, insurance practices capable of disrupting prescribed care, and identification policies vulnerable to administrative reversal.
Anti-trans government power does not operate only through explicit health-care bans. It also works through records, coverage restrictions, documentation demands, and policies that can disappear when political control changes hands. Illinois has moved to limit those mechanisms through medical privacy, continuity of care, and statutory protection.
Removing testosterone from state monitoring
HB 4834 excludes testosterone from the Illinois Prescription Monitoring Program, a state database that collects information about prescriptions for controlled substances. The law also excludes estrogen, gonadotropin-releasing hormone analogues, mifepristone, and misoprostol from the program.
Prescription databases can connect patients, providers, pharmacies, and treatment histories. When government actors target gender-affirming care, those records can identify trans patients and the medical professionals treating them.
Illinois officials said HB 4834 was intended to prevent out-of-state actors from using prescription information held in Illinois to punish people for receiving lawful gender-affirming care. Officials in hostile jurisdictions can still try to obtain records tied to care that was lawful in Illinois.
The law addresses that risk at the collection level. Illinois must remove existing testosterone prescribing and dispensing records from the monitoring system by January 1, 2027, while preventing new testosterone records from being maintained there. The measure took effect immediately.
That is stronger than a promise not to misuse the information. A restriction on access can be weakened or ignored; removing the record eliminates that database as a source from which it can later be retrieved.
For trans patients, the harm is concrete. A government-held testosterone record can reveal private medical care, expose a provider relationship, and create an official trail connecting a person to gender-affirming treatment. HB 4834 closes one state-controlled route through which that lawful care could be tracked.
Reducing treatment disruption
HB 5492 addresses another point of institutional control: the repeated insurance and pharmacy checkpoints through which prescribed hormone therapy can be delayed or interrupted.
The law requires qualifying health plans to cover up to a six-month supply of prescription hormone therapy, together with necessary supplies for self-administration, when prescribed by an authorized provider. Controlled substances remain limited to the maximum quantity allowed at one time under state and federal law.
HB 5492 takes effect January 1, 2027. Its principal coverage requirement applies to qualifying insurance policies amended, delivered, issued, or renewed in Illinois on or after January 1, 2028. The law therefore expands coverage through a phased implementation rather than creating immediate six-month access under every plan.
Longer covered supplies can reduce how often patients must return to insurers and pharmacies to maintain established treatment. Every refill, authorization, and coverage review creates another opportunity for care to be delayed by bureaucracy, shortages, policy changes, or institutional resistance.
Those barriers carry a distinct threat for trans people whose care is being targeted by government officials. A system built around frequent approvals gives political pressure more opportunities to interrupt prescribed treatment. HB 5492 reduces that vulnerability by requiring qualifying plans to cover a longer supply when prescribed as medically appropriate.
Making gender-marker protections harder to erase
HB 5095 addresses a third vulnerability: protections that exist only because the current administration chooses to maintain them.
The legislation establishes a gender-designation process for Illinois identification cards, driver’s licenses, and permits. Applicants may select “male,” “female,” or “X.” A person changing an existing marker must submit the required designation form, but the Secretary of State cannot demand additional medical certification or documentation beyond the statutory process.
This prevents the state from forcing trans and nonbinary people to secure medical approval before receiving identification that reflects who they are. It also places the process into law rather than leaving it entirely dependent on administrative policy.
That legal distinction matters. An agency practice can be withdrawn by a future officeholder with far less public scrutiny than a statute. Reversing a law ordinarily requires legislative action, recorded votes, and executive approval.
Accurate identification affects employment, housing, banking, health care, travel, traffic stops, and routine encounters with government agencies. When an identification document conflicts with a person’s identity, presenting it can disclose that they are trans without consent and expose them to harassment, discrimination, or danger.
HB 5095 reduces that harm by limiting invasive proof requirements and making the gender-marker process a legal duty of the state.
Three laws, one defensive structure
The three laws operate through different institutions, but they confront connected forms of control. HB 4834 limits government prescription surveillance. HB 5492 reduces insurance barriers that can destabilize hormone access. HB 5095 makes gender-marker protections more difficult for a future administration to erase.
Privacy, continuity of care, and accurate identification are not separate concerns for trans people. They are interconnected protections against systems that can track them, obstruct their treatment, or expose their identity.
Illinois has not ended the broader campaign against trans health care and legal recognition. Hostile government actors, courts, insurers, and future administrations can still attempt to undermine these protections. But the state has narrowed three channels through which institutional harm can occur by ordering testosterone records removed from a government monitoring system, requiring expanded coverage for prescribed hormone therapy, and placing gender-marker self-attestation into law.
These measures move beyond symbolic support by creating defensive legal infrastructure around the systems through which trans people can be monitored, denied continuity of care, or exposed by the state.
Trans people need enforceable protections against medical surveillance, treatment disruption, and administrative systems that can expose their identity or restrict their care.
Trans United documents the laws, institutions, and political actors shaping trans survival and public safety. Supporting this work sustains victim-centered reporting and public-record accountability.
Subscribe to Trans United ↓